Abstract:Abstract Background Identifying immunogens which can elicit effective T cell responses against human immunodeficiency virus type 1 (HIV-1) is important for developing a T-cell based vaccine. It has been reported that human leukocyte antigen (HLA)-B*13-restricted T-cell responses contributed to HIV control in subtype B′ and C infected individuals. However, the kinetics of B*13-restricted T-cell responses, viral evolution within epitopes, and the impact on disease progression in CRF01_AE subtype HIV-1-infected men who have sex with men (MSM) are not known. Results Interferon-γ ELISPOT assays and deep sequencing of viral RNAs were done in 14 early HLA-B*13-positive CRF01_AE subtype HIV-1-infected MSM. We found that responses to RQEILDLWV (Nef 106–114 , RV9), GQMREPRGSDI (Gag 226–236 , GI11), GQDQWTYQI (Pol 487–498 , GI9), and VQNAQGQMV (Gag 135–143 , VV9) were dominant. A higher relative magnitude of Gag-specific T-cell responses, contributed to viral control, whereas Nef-specific T-cell responses were associated with rapid disease progression. GI11 (Gag) was conserved and strong GI11 (Gag)-specific T-cell responses showed cross-reactivity with a dominant variant, M228I, found in 3/12 patients; GI11 (Gag)-specific T-cell responses were positively associated with CD4 T-cell counts ( R = 0.716, P = 0.046). Interestingly, the GI9 (Pol) epitope was also conserved, but GI9 (Pol)-specific T-cell responses did not influence disease progression ( P > 0.05), while a D490G variant identified in one patient did not affect CD4 T-cell counts. All the other epitopes studied [VV9 (Gag), RQYDQILIEI (Pol 113–122 , RI10), HQSLSPRTL (Gag 144–152 , HL9), and RQANFLGRL (Gag 429–437, RL9)] developed escape mutations within 1 year of infection, which may have contributed to overall disease progression. Intriguingly, we found early RV9 (Nef)-specific T-cell responses were associated with rapid disease progression, likely due to escape mutations. Conclusions Our study strongly suggested the inclusion of GI11 (Gag) and exclusion of RV9 (Nef) for T-cell-based vaccine design for B*13-positive CRF01_AE subtype HIV-1-infected MSM and high-risk individuals.

Research in relation HIV infection with small molecular peptides

[Preliminary Investigation on the Relation Between Clinical Progress and Anti-Small Monomolecular Peptides Antibody in Individual Infected with HIV].

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

The Serum Levels and Roles of Regulated Upon Activation Normal T Cell Expressed and Secreted and Monocyte Chemoattractant Protein-1 in Human Immunodeficiency Virus-1 Infected Patients

Understanding the molecular mechanism of the broad and potent neutralization of HIV-1 by antibody VRC01 from the perspective of molecular dynamics simulation and binding free energy calculations

The Expression And Clinical Significance Of Foxp3 Mrna In Peripheral Blood Monocytes From Hiv/Aids Patients

The Molecular Mechanism of Two Coreceptor Binding Site Antibodies X5 and 17b Neutralizing HIV-1: Insights from molecular dynamics simulation.

Computational Analysis of HIV-1 Resistance Based on Gene Expression Profiles and the Virus-Host Interaction Network

The Role of Peptides in Combatting HIV Infection: Applications and Insights

Study of the Cyclic Peptide Binding to HIV-1 Gp41 NHR

The Research of Anti-HIV Drugs Small Molecular CCR5 Antagonist

Structure-Function Study and Anti-Hiv Activity of Synthetic Peptide Analogues Derived from Viral Chemokine Vmip-Ii

Neutralizing antibodies mechanism of neutralization and protective activity against HIV-1.

The Research Progress of Antiviral Peptides

A longitudinal analysis of immune escapes from HLA-B*13-restricted T-cell responses at early stage of CRF01_AE subtype HIV-1 infection and implications for vaccine design

Genetic and Neutralization Sensitivity of Diverse HIV-1 env Clones from Chronically Infected Patients in China

Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses

Neutralization Sensitivity of HIV-1 CRF07_BC From an Untreated Patient With a Focus on Evolution Over Time

Effect of Amino Acid Replacements, Additions and Deletions on the Antiviral Activity of A Peptide Derived from the Hiv-1 Gp41 Sequence

Amino acid substitution of the membrane-proximal external region alter neutralization sensitivity in a chronic HIV-1 clade B infected patient

Fusion Peptide of HIV-1 As a Site of Vulnerability to Neutralizing Antibody